|
Mayo Clinic:
Fluoridation & Bone Disease in Renal Patients
DIRECTORY: FAN
> Health >
Bone >
Fluorosis
> Paper from Mayo Clinic
[SEE PHOTOCOPY OF STUDY]
American Association for the Advancement of Science (AAAS)
Evaluation of the Use of Fluorides. AAAS Selected
Symposium (1979)
Edited by E Johansen; DR Taves, & TO Olsen.
Fluoridation and bone disease in renal
patients.
By William J. Johnson, Donald R. Taves and Jenifer Jowsey
About the Authors:
William J Johnson,
director of the Mayo Artificial Kidney Center
and professor of medicine with the Division of Nephrology at the
Mayo Clinic, has been involved in the study of calcium and phosphorus
metabolism and renal osteodystrophy, potassium metabolism, and
uremic neuropathy. He is past chairman of the Minnesota State
Medical Association's Committee on Dialysis and Transplantation
and served on the editorial board of Nephron. He has published
over 70 papers in his field.
Jenifer Jowsey, director of orthopaedic research
at the Mayo Clinic and Mayo Foundation, has worked extensively
on metabolic bone disease, particularly the prevention and treatment
of osteoporosis. She received the Kappa Delta Award from the American
Academy of Orthopaedic Surgeons in 1975. She is the author of
some 230 publications including Metabolic Diseases of Bone (Saunders,
1977).
Donald R. Taves is associate professor of pharmacology
and toxicology and of radiation biology and biophysics at the
University of Rochester School of Medicine and Dentistry. He was
a member of a subcommittee of the National Academy of Sciences
Safe Drinking Water Study which examined the use of fluoride in
drinking water and his principal area of specialization is the
toxicology and pharmacology of fluoride.
\The Department of Nephrology at the Mayo Clinic examines approximately
100 new patients with end-stage renal disease each year. Some of
these patients reside in areas where the naturally occurring fluoride
concentration in tap water exceeds 1 ppm. During the course of several
years, six patients have been seen in whom fluoride may have been
the cause of detectable clinical and roentgenographic effects. Two
of these cases have been reported previously from our institution
(Juncos and Donadio, 1972). One patient had chronic glomerulonephritis,
and the others had congenital renal disease of more than 15 years'
duration before skeletal symptoms developed (Table 2). Most of the
patients had high urine volumes (>3 L per day), the fluid intake
being replaced by copious intake of water or in one instance, tea.
| Table 2. Causes of renal failure
in six patients exposed to high fluoride before dialysis. |
Cause
|
No. |
| Congenital defects of bladder, ureters |
3 |
| Fanconi syndrome |
1 |
| Bilateral polycystic kidneys |
1 |
| Chronic glomerulonephritis |
1 |
The most distinctive features suggesting fluorosis were the roentgenographic
appearance of the skeleton and the severity of dental mottling (Table
3). The most characteristic roentgenographic finding was a diffuse
increase in bone density which, in younger patients, assumed a ground-glass
appearance; whereas in older patients, it showed a coarse trabecular
pattern that became more obvious as the skeleton became more demineralized
over the years and with progression of renal failure. In addition
to the increase in bone density and the alteration of trabecular
pattern, there was a prominent new subperiosteal bone formation,
especially in the long bones in the upper and lower extremities,
and calcification of the interosseous ligaments between tibia and
fibula and between radius and ulna, as well as of the sacrotuberous
ligaments of the pelvis and the longitudinal ligaments of the spinal
column in some of the patients. In addition, three patients had
pseudofractures, a common feature of osteomalacia.
| Table 3. Roentgenographic findings in six patients
with renal failure who were exposed to high fluoride (1.7-2.0
ppm) before dialysis |
| Finding |
Patients |
| Increased bone density |
6 |
| Dental mottling |
2 |
| Calcified interosseous ligaments |
2 |
| Subperiosteal bone |
2 |
| Subperiosteal resorption |
0 |
| Fractures |
3 |
| Pseudofractures |
3 |
Despite having severe symptomatic bone disease, none of the patients
showed striking features of hyperparathyroidism, such as subperiosteal
resorption or bone cysts, which, in the United States, are the more
common manifestations of renal osteodystrophy. Plasma parathyroid
hormone concentrations, although elevated in all of the patients,
were relatively low considering the severity of the bone disease.
In addition, these patients developed severe skeletal changes or
bone pain early in the course of renal failure when creatinine values
were approximately 3 mg/dL. Symptoms referable to the skeleton varied.
Two of the six patients were asymptomatic; four complained of arthralgia,
especially of the knees, and of bone pain on weight-bearing involving
the lower extremities; three of the patients had spontaneous fractures
of metatarsals, ribs, and hip.
Bone biopsy specimens available from four patients showed a marked
increase in the ratio of fluoride to calcium (Table 4). Biopsy specimens
studied by quantitative microradiographic techniques showed a large
percentage of bone surface covered by osteoid as well as thick osteoid
seams with variable degrees of bone resorption and large areas of
new bone formation.
| Table 4. Patients exposed
to fluoride prior to dialysis |
| |
Fluoride |
Osteoid on bone biopsy |
| Case |
Water
(ppm) |
Serum
(uM) |
Bone*
(F/Ca) |
Surface
(%) |
Width
(uM) |
| 1 |
1.9 |
14.1 |
5.9 |
65.3 |
42 + 2.9 |
| 2 |
2.0 |
10.1 |
5.4 |
46.7 |
28.8 + 3.8 |
| 3 |
1.7 |
5.0 |
3.5 |
45.2 |
21.9 + 0.8 |
| 4 |
1.7 |
12.0 |
3.0 |
19.4 |
22.4 + 2.6 |
| Mean |
1.83 |
10.3 |
4.4 |
44.2 + 9.1 |
28.8 + 4.6 |
| Normal |
1.0 |
1.7 + 0.1 |
1.0 |
2.6 + 0.6 |
14.3 + 1.0 |
| * Fluoride is expressed as molar percent relative
to calcium (4.4 F/Ca = ~9,000 F bone ash) |
Therapeutic measures included the elimination of fluoride from
the drinking water, normalization of plasma calcium and phosphate
concentrations, and the use of vitamin D analogs. Symptoms were
lessened with these measures, but several patients continued to
have fractures. Four patients have been free of symptoms or fractures
since entering the dialysis program using fluoride-free dialysate
and continuing efforts to maintain normal calcium and phosphate
levels.
Case of Severest Disease.
A 69-year-old man experienced excessive frequent urge to urinate
associated with pyuria in 1958. Signs of infection cleared after
sulfonamide therapy, but urinary frequency, nocturia, and polyuria
persisted. The urine was of fixed specific gravity and showed a
trace of protein. Mild azotemia appeared in 1960, followed by bone
pain, arthralgia of the knees and feet, and spontaneous "march
fractures" of both feet - a total of 13 by 1963.
Examination of the urine revealed no infection, but a 24-hour specimen
showed an increased content of glucose and amino acid nitrogen.
The urine was alkaline, while the blood showed some evidence of
systemic acidosis. Blood sugar levels were normal, azotemia was
mild, and alkaline phosphatase activity was elevated, but values
for serum calcium, phosphate, and total protein were normal. An
excretory urogram showed small kidneys. Skeletal roentgenograms
showed healing fractures of the metatarsals and phalangeal bones
of both feet, areas of increased bone density with a coarse trabecular
pattern involving predominantly the axial skeleton and the calcification
of interosseous ligaments, and new subperiosteal bone formation.
Bone biopsy of the iliac crest showed an increase of uncalcified
osteoid tissue on bone surfaces, decreased mineral density around
osteocytes, low mineralization of cement lines, and much interstitium
with an irregular patttern.
After treatment with oral calcium supplements and vitamn D, bone
pain decreased but the patient experienced additional fractures.
Osteosclerosis increased, but serum alkaline phosphatase values
decreased to normal. A bone biopsy specimen taken in 1968 showed
healing of osteomalacia. Chemical values showed a high concentration
of fluoride in serum (14 uM) and bone (4.7 to 6.5 moles of fluoride
per 100 moles of calcium) and in drinking water (2 ppm or 106 uM)
relative to the concentration of fluoride in the urine (78 uM).
At this point, the patient was advised to stop drinking tap water
and to use only fluoride-free spring water or distilled water for
both drinking and cooking. Serum fluoride concentrations decreased
(to 8 uM), and for a period of approximately 8 years, the patient
was relatively free of bone pain and did not experience further
fractures.
In 1971, renal function temporarily deteriorated further. After
peritoneal dialysis, renal function spontaneously improved. In 1974,
the patient fell, sustaining a hip fracture that required internal
fixation. Osteomalacia has persisted despite vitamin D therapy and
reasonable control of systemic acidosis and secondary hyperparathyroidism.
These findings were interpreted as representing adult Fanconi's
syndrome wihth osteomalacia and superimposed fluorosis.
Concluding Remarks
The available evidence suggests that some patients wtih long-term
renal failure are being affected by drinking water with as little
as 2 ppm fluoride. All of the patients showed increased bone density,
and two showed calcification of interosseous ligaments which is
thought to be diagnostic of skeletal fluorosis. The average concentration
of fluoride in bone of 4.4 moles of fluoride per 100 moles of calcium
is equivalent to 9,000 ppm of fluoride on an ash weight basis and
is in the middle range of the values that have been reported for
advanced fluorosis. The excessive osteoid formation seen in these
patients is probably accentuated by fluoride.
... The meaning of these findings for community fluoridation will
depend on whether or not further work will clearly show adverse
effects in patients with renal failure drinking water with a concentration
of 1 ppm of fluoride and whether these effects can be easily avoided.
The finding of adverse effects in patients drinking water with 2
ppm of fluoride suggests that a few similar cases may be found in
patients imbibing 1 ppm, especially if large volumes are consumed,
or in heavy tea drinkers and if fluoride is indeed the cause.
It would seem prudent, therefore, to monitor the fluoride intake
of patients with renal failure living in high fluoride areas. The
serum concentration may indicate whether the patient should be advised
to drink low fluoride water and will provide a check regarding compliance.
Tentatively, a shift to low fluoride water should be made before
the serum fluoride concentration reaches 5 uM, since evidence of
fluorosis has been reported when the average serum concentrations
of fluoride are 8 uM.
|